objective: heparin and enoxaparin possess anti-inflammatory properties. we compared the effects of these drugs on inflammatory biomarkers in patients with st-segment elevated myocardial infarction (stemi). method: thirty four patients with stemi randomly separated in two groups and received standard doses of heparin and enoxaparin. the serum concentration of serum amyloid a (saa), c-reactive pr...

ABBREVIATIONS IN THIS CHAPTER ACS Acute coronary syndrome BMS Bare metal stent CABG Coronary artery bypass grafting DAPT Dual antiplatelet therapy DES Drug-eluting stent GPI Glycoprotein IIb/IIIa inhibitor HIT Heparin-induced thrombocytopenia NSTE ACS Non–ST-segment elevation acute coronary syndrome PCI Percutaneous coronary intervention STEMI ST-segment elevation myocardial infarction UA Unsta...

Heparin-induced thrombocytopenia (HIT) is an uncommon, yet dangerous side-effect of heparin therapy. The problems associated with the HIT patient while undergoing cardiopulmonary bypass increase dramatically when the patient is also of Jehovah's Witness faith. This case report depicts the techniques utilized and the decisions made over the course of a simple surgical procedure for an extremely ...

BACKGROUND AND OBJECTIVES The growing implantations of electrophysiological devices in the context of increasing rates of chronic antithrombotic therapy in cardiovascular disease patients underscore the importance of an effective periprocedural prophylactic strategy for prevention of bleeding complications. We assessed the risk of significant bleeding complications in patients receiving anti-pl...

CRD summary This review assessed the effect of using enoxaparin, a low molecular weight heparin, as an additional therapy with fibrinolytic treatment (such as streptokinase) in people with ST-segment elevation acute myocardial infarction. The authors concluded that enoxaparin was more effective than unfractionated heparin. However, the rates of major bleeding when using enoxaparin were signific...

BACKGROUND Many patients requiring pacemaker or implantable cardioverter-defibrillator (ICD) surgery are taking warfarin. For patients at high risk for thromboembolic events, guidelines recommend bridging therapy with heparin; however, case series suggest that it may be safe to perform surgery without interrupting warfarin treatment. There have been few results from clinical trials to support t...

HEPARIN, A GLYCOSAMINOGLYCAN OF VARYING POLYsaccharide units and molecular weights, has been shown to reduce ischemic events beyond that of aspirin alone in the setting of an acute coronary syndrome (ACS). This benefit translated into a class I indication for unfractionated heparin in the 2000 American College of Cardiology/American Heart Association (ACC/ AHA) treatment guidelines for non–ST-s...

Controversy exists as to whether and how long heparin treatment is necessary after infarct vessel recanalization. To determine the role of heparin, patients with suitable angiographic features after reperfusion therapy were randomly allocated to receive a brief infusion of intravenous heparin for less than or equal to 24 hours (group 1), adjusted to a partial thromboplastin time of 2 times cont...